Valeo Financial Advisors’s Myriad Genetics MYGN Stock Holding History

Valeo Financial Advisors’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-513	Closed	-$16K	–	1321
2021 Q1	$16K	Hold	513	–	–	﹤0.01%	1237
2020 Q4	$10K	Buy	513 +175	+52%	+$2.83K	﹤0.01%	1203
2020 Q3	$4K	Hold	338	–	–	﹤0.01%	1302
2020 Q2	$4K	Hold	338	–	–	﹤0.01%	1600
2020 Q1	$5K	Hold	338	–	–	﹤0.01%	1312
2019 Q4	$9K	Hold	338	–	–	﹤0.01%	1142
2019 Q3	$10K	Hold	338	–	–	﹤0.01%	1028
2019 Q2	$9K	Buy	338 +146	+76%	+$4.12K	﹤0.01%	1058
2019 Q1	$6K	Sell	192 -160	-45%	-$4.87K	﹤0.01%	1105
2018 Q4	$10K	Buy	352 +109	+45%	+$3.92K	﹤0.01%	886
2018 Q3	$11K	Buy	243 +83	+52%	+$3.69K	﹤0.01%	942
2018 Q2	$7K	Buy	+160	New	+$5.4K	﹤0.01%	1045

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

GCM

Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Valeo Financial Advisors's MYGN Position: Q2 2021 in Review

Valeo Financial Advisors sold out of Myriad Genetics (MYGN) in Q2 2021, closing a stake of 513 shares — an estimated $16K sold.

Valeo Financial Advisors first reported a position in MYGN in Q2 2018 and held it in 12 quarters. The position peaked at $16K in Q1 2021. 201 funds tracked by Wall St. Rank hold MYGN as of Q2 2021.

Valeo Financial Advisors reported no remaining Myriad Genetics position as of Q2 2021 after selling out during the quarter.
Valeo Financial Advisors sold 513 Myriad Genetics shares in Q2 2021, an estimated $16K.
Valeo Financial Advisors first reported a position in Myriad Genetics in Q2 2018 and held it in 12 quarters.
Valeo Financial Advisors's Myriad Genetics position peaked at $16K in Q1 2021.
201 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2021.

Based on Valeo Financial Advisors's 13F filing for Q2 2021, filed 22 Jul 2021.